Last reviewed · How we verify

PONATINIB HYDROCHLORIDE — Competitive Intelligence Brief

PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline.

marketed ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3 Small molecule Live · refreshed every 30 min

Target snapshot

PONATINIB HYDROCHLORIDE (PONATINIB HYDROCHLORIDE). Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PONATINIB HYDROCHLORIDE TARGET PONATINIB HYDROCHLORIDE marketed ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3 2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PONATINIB HYDROCHLORIDE — Competitive Intelligence Brief. https://druglandscape.com/ci/ponatinib-hydrochloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: